Luye Pharma Group Ltd. (HKG:2186)
Hong Kong · Delayed Price · Currency is HKD 1.750
+0.050 (2.94%)
Sep 18, 2026, 4:08 PM HKT
Luye Pharma Group Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 6,129 | 6,308 | 6,061 | 6,143 | 5,982 | 5,200 |
Revenue Growth | -2.84% | 4.07% | -1.33% | 2.70% | 15.03% | -6.13% |
Gross Profit Gross Profit Growth | 3,907 | 4,163 | 4,044 | 4,204 | 4,141 | 3,397 |
Operating Income Operating Income Growth | 1,167 | 1,218 | 1,137 | 887.44 | 789.14 | 363.4 |
Net Income Net Income Growth | 696.36 | 618.75 | 471.89 | 532.61 | 604.81 | -134.39 |
Earnings Per Share EPS Growth | 0.17 | 0.16 | 0.13 | 0.14 | 0.17 | -0.04 |
EPS Growth | 9.26% | 26.65% | -12.22% | -17.78% | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Oncology Drugs Oncology Drugs Growth | 1,838 | 2,297 | 2,085 | 2,122 | 2,306 | 1,414 |
Alimentary Tract and Metabolism Drugs Alimentary Tract and Metabolism Drugs Growth | 360.69 | 348.76 | 388.87 | 450.42 | 632.36 | 898.46 |
Cardio-Vascular System Drugs Cardio-Vascular System Drugs Growth | 1,194 | 1,152 | 1,660 | 1,687 | 1,536 | 1,427 |
Others Others Growth | 516.82 | 482.05 | 314.67 | 188.3 | 185.02 | 136.61 |
Central Nervous System Drugs Central Nervous System Drugs Growth | 2,220 | 2,028 | 1,613 | 1,695 | 1,323 | 1,324 |
Total Total Growth | 6,129 | 6,308 | 6,061 | 6,143 | 5,982 | 5,200 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 10,764 | 7,495 | 6,503 | 6,106 | 5,544 | 5,510 |
Total Debt Total Debt Growth | 11,987 | 10,315 | 10,321 | 8,424 | 9,105 | 9,491 |
Net Cash (Debt) Net Cash Growth | -1,223 | -2,820 | -3,818 | -2,318 | -3,560 | -3,980 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -0.30 | -0.72 | -1.01 | -0.62 | -1.02 | -1.16 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | - | 1,783 | 167.76 | 1,595 | 1,654 | 182.37 |
Capital Expenditures CapEx Growth | - | -511.4 | -594.07 | -632.66 | -655.68 | -556.2 |
Free Cash Flow Free Cash Flow Growth | - | 1,272 | -426.31 | 962.83 | 998.11 | -373.83 |
Free Cash Flow Growth | - | - | - | -3.54% | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 63.75% | 65.98% | 66.72% | 68.44% | 69.22% | 65.32% |
Operating Margin | 19.04% | 19.30% | 18.75% | 14.45% | 13.19% | 6.99% |
Pretax Margin | 16.35% | 14.97% | 13.85% | 11.40% | 11.20% | -1.43% |
Profit Margin | 11.36% | 9.81% | 7.79% | 8.67% | 10.11% | -2.58% |
FCF Margin | - | 20.16% | -7.03% | 15.67% | 16.69% | -7.19% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 8.74 | 15.90 | 16.26 | 23.91 | 19.00 | - |
Forward PE | 8.45 | 12.80 | 8.49 | 17.57 | 17.45 | 8.01 |
P/FCF Ratio | - | 7.73 | - | 13.23 | 11.51 | - |
PS Ratio | 0.99 | 1.56 | 1.26 | 2.07 | 1.92 | 1.98 |